<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>An2 Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/an2-therapeutics-inc</link>
<description>Latest news and press releases for An2 Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 31 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/an2-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835468278dffbe2df0e3032.webp</url>
<title>An2 Therapeutics Inc</title>
<link>https://6ix.com/company/an2-therapeutics-inc</link>
</image>
<item>
<title>AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-announces-initiation-of-phase-2-investigator-initiated-clinical-trial-of-epetraborole-for-mycobacterium-abscessus-complex-lung-disease</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-announces-initiation-of-phase-2-investigator-initiated-clinical-trial-of-epetraborole-for-mycobacterium-abscessus-complex-lung-disease</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule</description>
</item>
<item>
<title>AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-and-scientific-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-and-scientific-highlights</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>Phase 2 study of oral epetraborole in polycythemia vera (PV) expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027</description>
</item>
<item>
<title>AN2 Therapeutics Announces $40 Million Private Placement Financing</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-announces-dollar40-million-private-placement-financing</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-announces-dollar40-million-private-placement-financing</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule</description>
</item>
<item>
<title>AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-announces-plans-to-advance-oral-epetraborole-into-phase-2-study-for-polycythemia-vera-pv-27</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-announces-plans-to-advance-oral-epetraborole-into-phase-2-study-for-polycythemia-vera-pv-27</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>Substantial clinical evidence provides rationale to initiate Phase 2 study in PV Phase 2 study expected to begin 3Q26 with potential for data readouts as</description>
</item>
<item>
<title>AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-participate-fireside-chat-120000445</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-participate-fireside-chat-120000445</guid>
<pubDate>Tue, 17 Feb 2026 12:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., February 17, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026 at 3:40 PM ET.</description>
</item>
<item>
<title>AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-announces-fda-clearance-120000453</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-announces-fda-clearance-120000453</guid>
<pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., January 12, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the U.S. Food and Drug Administration has cleared Oregon Health & Science University’s (OHSU) Investigational New Drug (IND) application to proceed with an IIT that will evaluate the safety, efficacy, and pharmacokinetics of epetraborole in patients with Mycobacterium abscessus lung dis</description>
</item>
<item>
<title>AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-reports-third-quarter-210100164</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-reports-third-quarter-210100164</guid>
<pubDate>Wed, 12 Nov 2025 21:01:00 GMT</pubDate>
<description>MENLO PARK, Calif., November 12, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the third quarter ended September 30, 2025.</description>
</item>
<item>
<title>AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-announces-research-collaboration-120000367</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-announces-research-collaboration-120000367</guid>
<pubDate>Mon, 10 Nov 2025 12:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., November 10, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today announced a collaboration agreement with the global biopharma company GSK to develop new therapies for tuberculosis (TB). As part of this effort, the Gates Foundation will provide a third year of funding to support AN2’s work within the collaboration.</description>
</item>
<item>
<title>AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-participate-fireside-chat-220300751</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-participate-fireside-chat-220300751</guid>
<pubDate>Thu, 06 Nov 2025 22:03:00 GMT</pubDate>
<description>MENLO PARK, Calif., November 06, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will participate in a fireside chat at the 8th Annual Evercore HealthCONx Conference being held from December 2-4, 2025.</description>
</item>
<item>
<title>AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-reports-second-quarter-200100101</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-reports-second-quarter-200100101</guid>
<pubDate>Tue, 12 Aug 2025 20:01:00 GMT</pubDate>
<description>MENLO PARK, Calif., August 12, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the second quarter ended June 30, 2025.</description>
</item>
<item>
<title>AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-commences-first-human-110000999</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-commences-first-human-110000999</guid>
<pubDate>Tue, 12 Aug 2025 11:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., August 12, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has completed dosing the first single ascending dose cohort in its Phase 1 first-in-human clinical trial evaluating the safety, tolerability, and pharmacokinetics of oral AN2-502998 in healthy volunteers. AN2-502998 is a potentially curative drug candidate for chronic</description>
</item>
<item>
<title>AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-dndi-collaborate-clinical-110000700</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-dndi-collaborate-clinical-110000700</guid>
<pubDate>Wed, 23 Jul 2025 11:00:00 GMT</pubDate>
<description>MENLO PARK, Calif. & GENEVA, July 23, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX) and the non-profit medical research organization Drugs for Neglected Diseases initiative (DNDi) today announced a collaboration to advance clinical development of AN2-502998, AN2’s oral drug candidate in development for the treatment of chronic Chagas disease.</description>
</item>
<item>
<title>AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-reports-key-insights-110000495</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-reports-key-insights-110000495</guid>
<pubDate>Mon, 30 Jun 2025 11:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., June 30, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the completion of a 200-patient observational study in acute melioidosis, a highly lethal bacterial infection and recognized biothreat. The study, conducted under real-world conditions in acute hospital settings, evaluated patients receiving the current standard of care (SoC): I</description>
</item>
<item>
<title>AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-announces-poster-presentation-110000260</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-announces-poster-presentation-110000260</guid>
<pubDate>Thu, 29 May 2025 11:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., May 29, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company will present a poster highlighting the preclinical activity of epetraborole against M. abscessus on Thursday, May 29, 2025 at the Nontuberculous Mycobacteria Conference to be held May 27-30, 2025 at Colorado State University. It is estimated that M. a</description>
</item>
<item>
<title>AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-reports-first-quarter-200100323</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-reports-first-quarter-200100323</guid>
<pubDate>Tue, 13 May 2025 20:01:00 GMT</pubDate>
<description>MENLO PARK, Calif., May 13, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the first quarter ended March 31, 2025.</description>
</item>
<item>
<title>AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-reports-data-phase-200000802</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-reports-data-phase-200000802</guid>
<pubDate>Thu, 01 May 2025 20:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., May 01, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced topline results from the Phase 3 portion of the EBO-301 study evaluating epetraborole on top of an optimized background regimen (EBO+OBR) in treatment-refractory MAC lung disease.</description>
</item>
<item>
<title>AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-participate-citizens-jmp-110000939</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-participate-citizens-jmp-110000939</guid>
<pubDate>Wed, 30 Apr 2025 11:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., April 30, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2025 Citizens JMP Life Sciences Conference being held from May 7-8, 2025 in New York.</description>
</item>
<item>
<title>AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-reports-fourth-quarter-200000708</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-reports-fourth-quarter-200000708</guid>
<pubDate>Tue, 25 Mar 2025 20:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., March 25, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the fourth quarter and year ended December 31, 2024.</description>
</item>
<item>
<title>AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-present-leerink-partners-210000228</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-therapeutics-present-leerink-partners-210000228</guid>
<pubDate>Mon, 03 Mar 2025 21:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., March 03, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Leerink Partners Global Healthcare Conference.</description>
</item>
<item>
<title>AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease</title>
<link>https://6ix.com/company/an2-therapeutics-inc/news/an2-provides-strategic-phase-3-120000435</link>
<guid isPermaLink="true">https://6ix.com/company/an2-therapeutics-inc/news/an2-provides-strategic-phase-3-120000435</guid>
<pubDate>Mon, 24 Feb 2025 12:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., February 24, 2025--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its submission of an amended statistical analysis plan to the FDA selecting the Quality of Life – Bronchiectasis (QOL-B) respiratory domain patient reported outcome (PRO) instrument as the primary efficacy endpoint for the Phase 3 part of the EBO-301 trial. The C</description>
</item>
</channel>
</rss>